Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||AZD5305 + Darolutamide|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|AZD5305||AZD 5305|AZD-5305||PARP Inhibitor (Pan) 26||AZD5035 inhibits PARP, resulting in decreased DNA repair and accumulation of DNA damage, potentially leading to increased apoptosis (NCI Drug Dictionary).|
|Darolutamide||Nubeqa||BAY1841788|ODM-201||Hormone - Anti-androgens 38||Nubeqa (darolutamide) is an androgen receptor antagonist that binds to and prevents nuclear translocation of the androgen receptor, thereby inhibiting expression of genes downstream of androgen receptor signaling that regulate proliferation of prostate cancer cells (PMID: 28490267). Nubeqa (darolutamide) is FDA approved for use in patients with non-metastatic castration-resistant prostate cancer, and in combination with docetaxel in patients with metastatic hormone-sensitive prostate cancer (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05367440||Phase Ib/II||AZD5305 + Darolutamide Abiraterone + AZD5305 AZD5305 + Enzalutamide||Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA)||Recruiting||2|